自身免疫性肝炎的急性表现--从急性肝炎到 ALF 和 ACLF。

IF 5.9 2区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Hepatology International Pub Date : 2024-10-01 Epub Date: 2024-08-11 DOI:10.1007/s12072-024-10714-1
Atsushi Tanaka, Kenichi Harada
{"title":"自身免疫性肝炎的急性表现--从急性肝炎到 ALF 和 ACLF。","authors":"Atsushi Tanaka, Kenichi Harada","doi":"10.1007/s12072-024-10714-1","DOIUrl":null,"url":null,"abstract":"<p><p>Acute presentation of autoimmune hepatitis (AIH) occurs in 22-43% of all AIH cases, and is not a rare condition. Rather than constituting a single disease entity, it represents a clinical spectrum characterized by considerable variability in severity and the presence of preexisting chronic AIH. This spectrum ranges from acute AIH and acute severe AIH to AIH presenting as acute liver failure (ALF) or as acute-on-chronic liver failure (ACLF), contingent upon factors such as coagulopathy, hepatic encephalopathy, and underlying liver disease. Diagnosing acute presentation of AIH can be particularly challenging due to the frequent absence of classical serologic signatures such as autoantibodies and elevated IgG levels. Histopathological examination remains essential for diagnosis, typically necessitating percutaneous or transjugular liver biopsy. Corticosteroids (CS) are recommended for the management of acute AIH and acute severe AIH with coagulopathy. However, the therapeutic response to CS should be meticulously monitored. If a poor response is anticipated, liver transplantation (LT) should be promptly considered. For AIH presenting as ALF with encephalopathy or ACLF with advanced underlying liver disease, LT is generally advised. Nonetheless, there is potential for a trial of CS therapy in cases of ALF with low MELD scores or ACLF without encephalopathy. This review provides an overview of the latest findings concerning the definition, diagnosis, and management of acute presentation of AIH.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1385-1395"},"PeriodicalIF":5.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Acute presentation of autoimmune hepatitis -from acute hepatitis to ALF and ACLF.\",\"authors\":\"Atsushi Tanaka, Kenichi Harada\",\"doi\":\"10.1007/s12072-024-10714-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Acute presentation of autoimmune hepatitis (AIH) occurs in 22-43% of all AIH cases, and is not a rare condition. Rather than constituting a single disease entity, it represents a clinical spectrum characterized by considerable variability in severity and the presence of preexisting chronic AIH. This spectrum ranges from acute AIH and acute severe AIH to AIH presenting as acute liver failure (ALF) or as acute-on-chronic liver failure (ACLF), contingent upon factors such as coagulopathy, hepatic encephalopathy, and underlying liver disease. Diagnosing acute presentation of AIH can be particularly challenging due to the frequent absence of classical serologic signatures such as autoantibodies and elevated IgG levels. Histopathological examination remains essential for diagnosis, typically necessitating percutaneous or transjugular liver biopsy. Corticosteroids (CS) are recommended for the management of acute AIH and acute severe AIH with coagulopathy. However, the therapeutic response to CS should be meticulously monitored. If a poor response is anticipated, liver transplantation (LT) should be promptly considered. For AIH presenting as ALF with encephalopathy or ACLF with advanced underlying liver disease, LT is generally advised. Nonetheless, there is potential for a trial of CS therapy in cases of ALF with low MELD scores or ACLF without encephalopathy. This review provides an overview of the latest findings concerning the definition, diagnosis, and management of acute presentation of AIH.</p>\",\"PeriodicalId\":12901,\"journal\":{\"name\":\"Hepatology International\",\"volume\":\" \",\"pages\":\"1385-1395\"},\"PeriodicalIF\":5.9000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatology International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12072-024-10714-1\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12072-024-10714-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

急性自身免疫性肝炎(AIH)占所有 AIH 病例的 22-43%,并不罕见。它并不是一种单一的疾病实体,而是一个临床谱系,其特点是严重程度差异很大,并且存在原有的慢性自身免疫性肝炎。根据凝血功能障碍、肝性脑病和潜在肝病等因素的不同,这一范围从急性 AIH 和急性重度 AIH 到表现为急性肝衰竭 (ALF) 或急性慢性肝衰竭 (ACLF) 的 AIH 不等。由于经常缺乏典型的血清学特征,如自身抗体和 IgG 水平升高,诊断急性 AIH 尤为困难。组织病理学检查仍然是诊断的关键,通常需要经皮或经颈静脉肝活检。建议使用皮质类固醇(CS)治疗急性 AIH 和伴有凝血功能障碍的急性重症 AIH。但是,应仔细监测对皮质类固醇的治疗反应。如果预期反应不佳,应立即考虑肝移植(LT)。对于出现伴有脑病的 ALF 或伴有晚期基础肝病的 ACLF 的 AIH,一般建议进行 LT。尽管如此,对于MELD评分较低的ALF或无脑病的ACLF,仍有可能试用CS疗法。本综述概述了有关 AIH 急性表现的定义、诊断和管理的最新发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Acute presentation of autoimmune hepatitis -from acute hepatitis to ALF and ACLF.

Acute presentation of autoimmune hepatitis (AIH) occurs in 22-43% of all AIH cases, and is not a rare condition. Rather than constituting a single disease entity, it represents a clinical spectrum characterized by considerable variability in severity and the presence of preexisting chronic AIH. This spectrum ranges from acute AIH and acute severe AIH to AIH presenting as acute liver failure (ALF) or as acute-on-chronic liver failure (ACLF), contingent upon factors such as coagulopathy, hepatic encephalopathy, and underlying liver disease. Diagnosing acute presentation of AIH can be particularly challenging due to the frequent absence of classical serologic signatures such as autoantibodies and elevated IgG levels. Histopathological examination remains essential for diagnosis, typically necessitating percutaneous or transjugular liver biopsy. Corticosteroids (CS) are recommended for the management of acute AIH and acute severe AIH with coagulopathy. However, the therapeutic response to CS should be meticulously monitored. If a poor response is anticipated, liver transplantation (LT) should be promptly considered. For AIH presenting as ALF with encephalopathy or ACLF with advanced underlying liver disease, LT is generally advised. Nonetheless, there is potential for a trial of CS therapy in cases of ALF with low MELD scores or ACLF without encephalopathy. This review provides an overview of the latest findings concerning the definition, diagnosis, and management of acute presentation of AIH.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hepatology International
Hepatology International 医学-胃肠肝病学
CiteScore
10.90
自引率
3.00%
发文量
167
审稿时长
6-12 weeks
期刊介绍: Hepatology International is the official journal of the Asian Pacific Association for the Study of the Liver (APASL). This is a peer-reviewed journal featuring articles written by clinicians, clinical researchers and basic scientists is dedicated to research and patient care issues in hepatology. This journal will focus mainly on new and emerging technologies, cutting-edge science and advances in liver and biliary disorders. Types of articles published: -Original Research Articles related to clinical care and basic research -Review Articles -Consensus guidelines for diagnosis and treatment -Clinical cases, images -Selected Author Summaries -Video Submissions
期刊最新文献
AARC score and urine NGAL predict terlipressin non-response and mortality in patients with acute-on-chronic liver failure. Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study. Global, regional, and national epidemiology of hepatoblastoma in children from 1990 to 2021: a trend analysis. Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy. The dynamic patterns of metabolic-associated fatty liver disease and its severity and risk of cardiovascular disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1